Kur-Ta Cheng

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with few treatment options. A promising TNBC treatment approach is targeting the oncogenic signaling pathways pivotal to TNBC initiation and progression. Deregulated activation of signal transducer and activator of transcription 3 (STAT3) is fundamental to driving TNBC malignant transformation, highlighting STAT3 as a promising TNBC therapeutic target. Methoxyhispolon Methyl Ether (MHME) is an analog of Hispolon, an anti-cancer polyphenol found in the medicinal mushroom Phellinus linteus. Still, MHME’s anti-cancer effects and mechanisms remain unknown. Herein, we present the first report about MHME’s anti-TNBC effect and its action mechanism. We first revealed that MHME is proapoptotic and cytotoxic against human TNBC cell lines HS578T, MDA-MB-231, and MDA-MB-463 and displayed a more potent cytotoxicity than Hispolon’s. Mechanistically, MHME suppressed both constitutive and interleukin 6 (IL-6)-induced activation of STAT3 represented by the extent of tyrosine 705-phosphorylated STAT3 (p-STAT3). Notably, MHME-evoked apoptosis and clonogenicity impairment were abrogated in TNBC cells overexpressing a dominant-active mutant of STAT3 (STAT3-C); supporting the blockade of STAT3 activation is an integral mechanism of MHME’s cytotoxic action on TNBC cells. Moreover, MHME downregulated BCL-2 in a STAT3-dependent manner, and TNBC cells overexpressing BCL-2 were refractory to MHME-induced apoptosis, indicating that BCL-2 downregulation is responsible for MHME’s proapoptotic effect on TNBC cells. Finally, MHME suppressed SRC activation, while v-src overexpression rescued p-STAT3 levels and downregulated apoptosis in MHME-treated TNBC cells. Collectively, we conclude that MHME provokes TNBC cell apoptosis through the blockade of the SRC/STAT3/BCL-2 pro-survival axis. Our findings suggest the potential of applying MHME as a TNBC chemotherapy agent.

Colorectal cancer (CRC) is the third most prevalent human cancer globally. 5-Fluorouracil (5-FU)-based systemic chemotherapy is the primary strategy for advanced CRC treatment, yet is limited by poor response rate. Deregulated activation of signal transducer and activator of transcription 3 (STAT3) is fundamental to driving CRC malignant transformation and a poor prognostic marker for CRC, underscoring STAT3 as a promising CRC drug target. Dehydroxyhispolon methyl ether (DHME) is an analog of Hispolon, an anticancer polyphenol abundant in the medicinal mushroom Phellinus linteus. Previously, we have established DHME’s cytotoxic effect on human CRC cell lines by eliciting apoptosis through the blockade of WNT/β-catenin signaling, a preeminent CRC oncogenic pathway. Herein, we unraveled that compared with 5-FU, DHME is a more potent killer of CRC cells while being much less toxic to normal colon epithelial cells. DHME suppressed both constitutive and interleukin 6 (IL-6)-induced STAT3 activation represented by tyrosine 705 phosphorylation of STAT3 (p-STAT3 (Y705)); notably, DHME-induced CRC apoptosis and clonogenicity limitation were abrogated by ectopic expression of STAT3-C, a dominant-active STAT3 mutant. Additionally, we proved that BCL-2 downregulation caused by DHME-mediated STAT3 blockage is responsible for DHME-induced CRC cell apoptosis. Lastly, DHME inhibited SRC activation, and v-src overexpression restored p-STAT3 (Y705) levels along with lowering the levels of apoptosis in DHME-treated CRC cells. We conclude DHME provokes CRC cell apoptosis by blocking the SRC/STAT3/BCL-2 axis besides thwarting WNT/β-catenin signaling. The notion that DHME targets two fundamental CRC signaling pathways underpins the potential of DHME as a CRC chemotherapy agent.

In a previous study, we evaluated the effect of baicalin on the expression of SP-A (surfactant protein A), which was developmentally regulated in an alveolar type II cell, H441. SP-A is encoded by two similar genes, SP-A1 and SP-A2, in humans. The maximal induction of SP-A1 gene of H441 occurred at treating 150 nM of baicalin for 48 h. In the present study, cDNA subtraction analysis is performed to examine the differential expression in H441 cell upon baicalin treatment with a view to investigating the regulatory mechanism. The mRNA of H441 cell incubated with 150 nM baicalin for 48 h was compared to that of blank control. Two PCR products were obtained through subtractive cDNA amplification. A product encoding cytochrome c oxidase was demonstrated to be a differential signal by RT-PCR analysis, and the other was a false positive. The induction of cytochrome c oxidase might increase ATP level in cell, and consequently elevates cAMP, which upregulates surfactant synthesis and secretion. Keywords: Baicalin; cytochrome c oxidase; cDNA subtraction

Pulmonary surfactant, a complex lipoprotein, is secreted by alveolar type II cells. It lies at the alveolar air-fluid interface and prevents alveolar collapse by reducing surface tension. The high incidence of respiratory distress syndrome (RDS) in premature infants results principally from a deficiency of pulmonary surfactant. Surfactant protein A (SP-A) is the most abundant surfactant protein and reduces surface tension at the alveolar air-liquid interface in lung cells. In this study, RT-PCR and Western blot analyses of SP-A were performed to evaluate the biological activity of baicalin, a Chinese medicine prescribed extensively for preventing miscarriage. In in vitro experiments, lung adenocarcinoma cell line H441 was cultured with baicalin in varying concentrations and for varying lengths of time. The results show that the expression of SP-A gene was positively affected by baicalin in dose-dependent and time-course manners. The maximal expression of the SP-A gene, 1.7-fold greater than control, is induced at 150 nM of baicalin treated for 48 h. SP:surfactant protein RDS:respiratory distress syndrome IFN-γ:insulin, interferon gamma TGF-β1:transforming growth factor β1 db-cAMP:dibutyryl adenosine 3′,5′-monophosphate RT-PCR:reverse transcription-polymerase chain reaction